SFCA3006: Significantly Greater Improvement in Pre-Dose FEV1 Seen with FP500 vs. Placebo

Endpoint

(2%)

(11%)

*Pɘ.001 vs PLA

? FEV1 (ml)

*

Previous slide

Next slide

Back to first slide

View graphic version